Bone Mass Continues to Increase at the Hip After Parathyroid Hormone Treatment Is Discontinued in Glucocorticoid‐Induced Osteoporosis: Results of a Randomized Controlled Clinical Trial
暂无分享,去创建一个
H. Genant | N. Lane | G. Modin | C. Arnaud | S. Sanchez | Elena Pierini
[1] P. Sambrook. Glucocorticoid osteoporosis. , 2002, Current pharmaceutical design.
[2] J. Finkelstein,et al. Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. , 1999, The Journal of clinical endocrinology and metabolism.
[3] H. Genant,et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. , 1998, The Journal of clinical investigation.
[4] Jacques P. Brown,et al. Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1998 .
[5] A. Parfitt,et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. , 1998, The Journal of clinical investigation.
[6] C. Moniz,et al. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long term oral corticosteroid treatment , 1998, Thorax.
[7] R. Lindsay,et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis , 1997, The Lancet.
[8] Jacques P. Brown,et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. , 1997, The New England journal of medicine.
[9] E. Leib,et al. Calcium and Vitamin D3 Supplementation Prevents Bone Loss in the Spine Secondary to Low-Dose Corticosteroids in Patients with Rheumatoid Arthritis , 1996, Annals of Internal Medicine.
[10] S. Cummings,et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.
[11] Robert Epstein,et al. Comparison of methods for defining prevalent vertebral deformities: The study of osteoporotic fractures , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[12] T. Spector,et al. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. , 1994, Arthritis and rheumatism.
[13] J. Eisman,et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. , 1993, The New England journal of medicine.
[14] J. Adachi,et al. Corticosteroid-induced osteoporosis. , 1993, Seminars in arthritis and rheumatism.
[15] R. Robinson,et al. Estrogen and progesterone replacement therapy reduces glucocorticoid‐induced bone loss , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[16] L. Raisz,et al. Glucocorticoid-induced osteoporosis: pathogenesis and management. , 1990, Annals of internal medicine.
[17] R M Neer,et al. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1–34) and 1,25‐dihydroxyvitamin D , 1986, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[18] J. Parsons,et al. A Bioassay for Parathyroid Hormone using Chicks , 1973 .
[19] J. Parsons,et al. A chick bioassay for parathyroid hormone. , 1973, Endocrinology.
[20] S. Krane,et al. An evaluation of antibodies and clinical resistance to salmon calcitonin. , 1972, The Journal of clinical investigation.